Familial Adenomatous Polyposis is an inherited disorder characterized by cancer of the large intestine and rectum. It is a genetic condition. It is diagnosed when a person develops more than 100 adenomatous colon polyps.
An adenomatous polyp is an area where normal cells that line the inside of a person’s colon form a mass on the inside of the intestinal tract. On average, polyps develop in people with Familial Adenomatous Polyposis in their mid-teens. Most people with FAP will have multiple colon polyps by age 35.
If Familial Adenomatous Polyposis is not recognized and treated, there is a very high likelihood that a person will develop colorectal cancer.
Familial Adenomatous Polyposis Epidemiology Segmentation in the 7MM from 2018 to 2030
- Prevalent Cases of Familial Adenomatous Polyposis
- Diagnosed Cases of Familial Adenomatous Polyposis
- Etiology-Specific Prevalence of Familial Adenomatous Polyposis
- Type-specific Prevalence of Familial Adenomatous Polyposis
Familial Adenomatous Polyposis Epidemiology Insights Observed in 2020
- The total Familial Adenomatous Polyposis cases in the 7MM were observed to be 60,661.
- As per DelveInsight analysts, the United States had the highest Familial Adenomatous Polyposis incident population in the 7MM.
- Among the EU5 countries, Germany had the highest Familial Adenomatous Polyposis incident population whereas the number of FAP cases observed in Spain was supposed to be 1,725 in the year 2020
Familial Adenomatous Polyposis Market Insights
Familial Adenomatous Polyposis market size was found to be USD 33.8 million in 7MM in the year 2020.
Familial Adenomatous Polyposis Emerging Therapies
The emerging drugs in the Familial Adenomatous Polyposis market are
- eRapa
- CPP-1X/sul
- Eicosapentaenoic acid, and several others
Familial Adenomatous Polyposis Key Players
The key companies in the Familial Adenomatous Polyposis market are
- Emtora Biosciences
- Cancer Prevention Pharmaceuticals
- SLA Pharma, and many others